MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Cue Biopharma, Inc. (NASDAQ: CUE)
Organization & Developments: Cue Biopharma
Parents
Cue Biopharma, Inc. (NASDAQ: CUE)
Children
*Clinical-stage company working on new treatments in the field of immunotherapy, specifically a new class of injectable biologic medications that will directly engage and modulate selected T-cells.
*Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body to transform the treatment of cancer.
*This approach has applications in multiple fields, including cancer treatment, infectious diseases, and autoimmune disorders.
2022: Cue Biopharma Granted FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma_gcs-web
2024: Cue Biopharma lays off employees – NBC Boston
2024: Cue Biopharma: Not Exactly Sinking The Money Ball Yet_seekingalpha.com
Jumps
Finance & Acquisitions: Cue Biopharma
Key People: Cue Biopharma